Gentian Diagnostics ASA

Gentian Diagnostics ASA is a Norwegian medical diagnostics company founded in 2001 and headquartered in Moss, specializing in the development and manufacture of high-quality in vitro diagnostic (IVD) reagents using proprietary PETIA (particle-enhanced turbidimetric immunoassay) technology based on nanoparticle expertise. This innovation adapts clinically relevant biomarkers for efficient, high-throughput automated analyzers, improving laboratory productivity in detecting infections, inflammation, kidney failure, heart failure, and veterinary conditions. Its established portfolio includes Cystatin C for kidney function, fCAL turbo and GCAL for fecal calprotectin in inflammatory bowel disease, fPELA turbo, and Canine CRP, contributing to 26% annual revenue growth from 2019 to 2024. Products in development, such as NT-proBNP, target growth opportunities in a USD 1.8 billion serviceable market expanding at 5-10% annually. Gentian serves global human and veterinary diagnostics markets via sales offices in Sweden, the USA, and China, with a team of 63 employees led by CEO Njaal Kind, drawing expertise from leading IVD firms to drive scalable innovation. Since its 2016 IPO, the company plays a key role in enhancing diagnostic efficiency and cost savings in healthcare.